- In May 2024, BioNano Therapeutics Inc., a U.S.-based nanomedicine company, announced the successful completion of a Phase I clinical trial for its red blood cell membrane-coated nanoparticle formulation designed for targeted delivery of chemotherapy drugs. The trial demonstrated enhanced circulation time and reduced off-target toxicity, marking a significant advancement in biomimetic delivery technologies. This development reflects the growing emphasis on biocompatible, cell-inspired systems to improve therapeutic index in oncology
- In April 2024, a strategic research collaboration was formed between the University of Cambridge and Genova Biologics (UK) to develop platelet-mimicking nanocarriers for use in cardiovascular disease therapies. These carriers aim to target damaged vasculature and deliver anti-thrombotic agents more precisely. The partnership underscores a broader trend toward bio-inspired drug delivery in non-oncological indications, expanding the clinical scope of biomimetic nanocarriers
- In March 2024, NanoMem Therapeutics Ltd. (Japan) unveiled a new class of exosome-mimicking nanocarriers at the BIO Asia–Taiwan Conference, showcasing preclinical data supporting their potential in neurodegenerative disease treatment. The biomimetic platform demonstrated strong blood-brain barrier penetration and targeted delivery of anti-inflammatory agents. This innovation highlights Japan's commitment to leveraging nanobiotechnology for central nervous system (CNS) disorders
- In February 2024, Cellicon Therapeutics (Germany) received funding from the European Innovation Council to advance development of its immune cell-derived nanocarriers for use in autoimmune diseases. The funding will support preclinical studies and scale-up processes. Cellicon’s approach uses leukocyte-mimicking particles to improve immunomodulation, reflecting Europe’s push toward next-generation biologic delivery systems
- In January 2024, India’s Council of Scientific and Industrial Research (CSIR), in collaboration with private sector firm Biocura Labs, launched a pilot project to develop cancer-targeting biomimetic nanoparticles using indigenous raw materials. The initiative is part of India’s broader strategy to strengthen domestic nanomedicine capabilities while addressing affordability and scalability. This development signals growing interest in localized, cost-effective biomimetic solutions tailored for emerging markets
